Original Source(s)
Related Content
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min
Most Miss Streamlined Neck Mass Dx Path
Same-visit biopsy and fewer empiric workup steps were linked to faster pathologic diagnosis in a retrospective analysis.
June 19, 2026
-
5 min
FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI
The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.
June 15, 2026
-
3 min